Dracen Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.dracenpharma.com
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced Solid TumorNon Small Cell Lung Cancer Metastatic
- Interventions
- Biological: atezolizumab
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Dracen Pharmaceuticals, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT04471415
- Locations
- 🇩🇪
University Hospital Frankfurt, Frankfurt, Germany
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath